Kezar to commence Phase IIa autoimmune hepatitis therapy trial

Kezar Life Sciences has announced plans to commence the Phase IIa PORTOLA clinical trial (KZR-616-208) of zetomipzomib to treat autoimmune hepatitis.

The move comes after the US Food and Drug Administration granted clearance for the Investigational New Drug (IND) application of Kezar Life Sciences for zetomipzomib.